In the at-risk phase before clinical RA development, the presence of autoantibodies such as anti-citrullinated protein antibodies (ACPA) and/or IgM-rheumatoid factor (RF) with or without arthralgia symptoms predict the development of RA [1–4]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.